Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
T2 Biosystems Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
TTOO
Nasdaq
3845
https://www.t2biosystems.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for T2 Biosystems Inc
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
- Apr 24th, 2024 1:00 pm
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
- Apr 11th, 2024 8:05 pm
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- Mar 28th, 2024 1:00 pm
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
- Mar 20th, 2024 11:30 am
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
- Mar 19th, 2024 1:00 pm
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
- Mar 18th, 2024 1:00 pm
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
- Mar 12th, 2024 1:00 pm
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
- Feb 16th, 2024 2:29 pm
Q4 2023 T2 Biosystems Inc Earnings Call
- Feb 16th, 2024 11:08 am
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Feb 15th, 2024 9:06 pm
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
- Feb 15th, 2024 9:04 pm
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
- Feb 15th, 2024 9:02 pm
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
- Feb 12th, 2024 2:00 pm
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
- Feb 7th, 2024 9:05 pm
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
- Feb 7th, 2024 2:00 pm
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients
- Jan 18th, 2024 2:00 pm
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
- Jan 3rd, 2024 2:00 pm
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Nov 3rd, 2023 1:00 pm
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements
- Nov 1st, 2023 1:00 pm
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
- Oct 24th, 2023 8:05 pm
Scroll